8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 15, 2026·SEC
Material company update
Mar 16, 2026·SEC
Structure Therapeutics Inc.(GPCR)Earnings, Financials & Key Ratios
GPCR•NASDAQ
Price updated Jun 19, 2026
AboutStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$284M-80.4%
- Net Income-$141M-15.2%
- EPS (Diluted)-2.40-2.6%
- ROE-11.86%+36.2%
GPCR Key Insights
Structure Therapeutics Inc. (GPCR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 54.8% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 12.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GPCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GPCR Price & Volume
Structure Therapeutics Inc. (GPCR) stock price & volume — 10-year historical chart
Loading chart...
GPCR Growth Metrics
Structure Therapeutics Inc. (GPCR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-19.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.33%
Return on Capital
10 Years-40.21%
5 Years-39.32%
3 Years-28.63%
Last Year-24.09%
GPCR Recent Earnings
Structure Therapeutics Inc. (GPCR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.35+10.3%
$0.39
Rev
—
$11M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.49-40.0%
$0.35
Rev
—
$9M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.37-2.8%
$0.36
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.36-28.6%
$0.28
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.35vs $0.39+10.3% | —vs $11M |
| Q1 2026 | Feb 26, 2026 | $0.49vs $0.35-40.0% | —vs $9M |
| Q4 2025 | Nov 6, 2025 | $0.37vs $0.36-2.8% | — |
| Q3 2025 | Aug 6, 2025 | $0.36vs $0.28-28.6% | — |
Based on last 12 quarters of dataView full earnings history →
GPCR Peer Comparison
Structure Therapeutics Inc. (GPCR) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CHRS | 181.17M | 1.48 | -1.02 | -84.2% | -323.49% | -174.71% | 0.66 | |
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 CGEM | 923.71M | 15.03 | -4.04 | -51.45% | 0.01 | |||
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 PEPG | 123.81M | 1.79 | -0.84 | -59.89% | 0.12 | |||
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 |
Compare GPCR vs Peers
Structure Therapeutics Inc. (GPCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GPCR Income Statement
Structure Therapeutics Inc. (GPCR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 20.03K | 0 | 0 | 0 | 0 | 3.9M | 1.22M |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | -20.03K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -3.9M▲ 0% | -1.22M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | 100% | - | - | - | - | - |
Operating Expenses | 15.91M | 37.7M | 52.56M | 102.78M | 158.23M | 283.67M | 208.68M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 3.53M | 8.59M | 16.37M | 32.67M | 49.41M | 61.55M | 70.98M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 12.39M | 29.11M | 36.19M | 70.1M | 108.81M | 225.25M | 249.09M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -3.14M | -2M |
Operating Income | -15.93M▲ 0% | -37.7M▼ 136.6% | -52.56M▼ 39.4% | -102.78M▼ 95.5% | -158.23M▼ 54.0% | -287.57M▼ 81.7% | -209.89M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -136.59% | -39.43% | -95.53% | -53.96% | -81.74% | - |
EBITDA | -15.91M | -37.62M | -52.28M | -102.48M | -157.24M | -283.67M | -207.68M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | -136.43% | -38.96% | -96.01% | -53.43% | -80.41% | -14.44% |
D&A (Non-Cash Add-back) | 20.03K | 72K | 277K | 295K | 992K | 3.9M | 2.21M |
EBIT | -15.77M | -37.7M | -52.56M | -102.78M | -158.23M | -140.69M | -192.53M |
Net Interest Income | 168K | -122.04K | 1.26M | -11.64K | 36.01M | 35.97M | 41.15M |
Interest Income | 168.29K | 122 | 1.26M | 13.38M | 36.03M | 35.97M | 41.15M |
Interest Expense | 0 | 122.16K | 0 | 13.39M | 0 | 0 | 0 |
Other Income/Expense | 168.29K | -122K | 1.26M | 13.39M | 36.01M | 146.51M | 39.94M |
Pretax Income | -15.77M▲ 0% | -37.82M▼ 139.9% | -51.3M▼ 35.7% | -89.38M▼ 74.2% | -122.22M▼ 36.7% | -140.69M▼ 15.1% | -169.96M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 138.24K | 231K | 17K | 236K | 310K | 515K | 607.57K |
Effective Tax Rate % | -0.88% | -0.61% | -0.03% | -0.26% | -0.25% | -0.37% | -0.36% |
Net Income | -15.9M▲ 0% | -40.01M▼ 151.6% | -51.32M▼ 28.3% | -89.62M▼ 74.6% | -122.53M▼ 36.7% | -141.2M▼ 15.2% | -170.56M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -151.57% | -28.28% | -74.63% | -36.72% | -15.24% | -19.01% |
Net Income (Continuing) | -15.9M | -38.05M | -51.32M | -89.62M | -122.53M | -141.2M | -170.56M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.45▲ 0% | -1.20▼ 166.7% | -1.44▼ 20.0% | -2.43▼ 68.8% | -2.34▲ 3.7% | -2.40▼ 2.6% | -2.35▲ 0% |
EPS Growth % | - | -166.67% | -20% | -68.75% | 3.7% | -2.56% | -2.33% |
EPS (Basic) | -0.45 | -1.20 | -1.44 | -2.43 | -2.34 | -2.40 | - |
Diluted Shares Outstanding | 36.59M | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M | 72.44M |
Basic Shares Outstanding | 36.59M | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M | 72.44M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
GPCR Balance Sheet
Structure Therapeutics Inc. (GPCR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 38.42M | 109.25M | 93.09M | 473.61M | 891.21M | 1.57B | 1.49B |
Cash & Short-Term Investments | 37.45M | 107.31M | 90.84M | 467.32M | 883.52M | 1.45B | 1.46B |
Cash Only | 16.35M | 105.31M | 26.09M | 129.79M | 169.51M | 799.62M | 316.17M |
Short-Term Investments | 21.09M | 2M | 64.75M | 337.53M | 714.01M | 646.57M | 1.14B |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.25M | 6.29M | 7.69M | 124.11M | 32.09M |
Total Non-Current Assets | 285K | 1.91M | 4.76M | 8.41M | 12.12M | 13.62M | 17.53M |
Property, Plant & Equipment | 277K | 1.79M | 1.29M | 8.36M | 7.01M | 12.9M | 11.97M |
Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 8K | 111K | 3.46M | 45K | 5.11M | 717K | 5.55M |
Total Assets | 38.7M▲ 0% | 111.16M▲ 187.2% | 97.84M▼ 12.0% | 482.02M▲ 392.6% | 903.33M▲ 87.4% | 1.58B▲ 75.3% | 1.51B▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 187.19% | -11.97% | 392.63% | 87.41% | 75.34% | 124.76% |
Total Current Liabilities | 3.04M | 8.66M | 13.01M | 24.74M | 36.02M | 63.28M | 56.98M |
Accounts Payable | 1.53M | 3.48M | 6.01M | 4.74M | 8.02M | 13.86M | 7.82M |
Days Payables Outstanding | 27.82K | - | - | - | - | 1.3K | 3.63K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.88M | 2.61M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 819K | 1.94M | 3.54M | 4.33M | 7.29M | 46.54M | 46.55M |
Current Ratio | 12.64x | 12.62x | 7.16x | 19.14x | 24.74x | 24.81x | 26.16x |
Quick Ratio | 12.64x | 12.62x | 7.16x | 19.14x | 24.74x | 24.81x | 26.16x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 58.13M | 167.23M | 199.97M | 4.31M | 2.47M | 4.26M | 4.05M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 3.61M | 3.18M |
Capital Lease Obligations | 133K | 272K | 0 | 4.01M | 2.16M | 0 | 5.01M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 58M | 166.96M | 199.97M | 298K | 302K | 647K | 863K |
Total Liabilities | 61.17M | 175.89M | 212.99M | 29.05M | 38.49M | 67.54M | 61.03M |
Total Debt | 280K | 621K | 260K | 5.45M | 3.86M | 6.49M | 5.79M |
Net Debt | -16.07M | -104.68M | -25.83M | -124.34M | -165.65M | -793.14M | -310.38M |
Debt / Equity | - | - | - | 0.01x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | 1.49x |
Interest Coverage | - | -308.58x | - | -7.67x | - | - | - |
Total Equity | -22.47M▲ 0% | -64.73M▼ 188.1% | -115.14M▼ 77.9% | 452.97M▲ 493.4% | 864.84M▲ 90.9% | 1.52B▲ 75.3% | 1.45B▲ 0% |
Equity Growth % | - | -188.11% | -77.86% | 493.4% | 90.93% | 75.34% | 120.51% |
Book Value per Share | -0.61 | -1.77 | -3.15 | 12.33 | 16.43 | 25.62 | 19.98 |
Total Shareholders' Equity | -22.47M | -64.73M | -115.14M | 452.97M | 864.84M | 1.52B | 1.45B |
Common Stock | 1K | 1K | 1K | 14K | 17K | 21K | 21K |
Retained Earnings | -22.95M | -64.74M | -116.95M | -206.57M | -329.1M | -470.3M | -546.27M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1K | 0 | -110K | 521K | 914K | 1.05M | -2.19M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GPCR Cash Flow Statement
Structure Therapeutics Inc. (GPCR) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -14.28M | -32.16M | -46.12M | -79.49M | -116.64M | -222.2M | -154.69M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -125.16% | -43.41% | -72.35% | -46.73% | -90.51% | -213.02% |
Net Income | -15.88M | -38.05M | -51.32M | -89.62M | -122.53M | -141.2M | -170.56M |
Depreciation & Amortization | 0 | 72K | 277K | 295K | 992K | 1.33M | 2.28M |
Stock-Based Compensation | 570K | 1.49M | 2.51M | 8.19M | 18.79M | 28.99M | 23.07M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 77K | 268K | -558K | -5.32M | -16.86M | -23.05M | -9.82M |
Working Capital Changes | 946K | 4.06M | 2.97M | 6.97M | 2.96M | -88.27M | 344.97K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 100.3M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.02M | 1.9M | 2.15M | -859.25K | 3.31M | 4.76M | -902.81K |
Cash from Investing | -21.15M | 17.86M | -62.11M | -268.34M | -358.91M | 89.8M | -442.67M |
Capital Expenditures | -19K | -1.21M | -155K | -2.17M | -1.29M | -3.61M | -4.49M |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | -231.38K | 0 | 10.25M | 10.25M |
Cash from Financing | 25.84M | 103.25M | 29.01M | 451.53M | 515.26M | 762.52M | 759.96M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 25.84M | 103.36M | 31.5M | 472.3M | 514.57M | 767.18M | 767.33M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -104K | -2.49M | -20.77M | 690K | -4.66M | -7.37M |
Net Change in Cash | -9.59M▲ 0% | 88.95M▲ 1027.3% | -79.21M▼ 189.1% | 103.7M▲ 230.9% | 39.72M▼ 61.7% | 630.12M▲ 1486.5% | 164.05M▲ 0% |
Free Cash Flow | -14.3M▲ 0% | -33.37M▼ 133.3% | -46.27M▼ 38.7% | -81.66M▼ 76.5% | -117.93M▼ 44.4% | -225.81M▼ 91.5% | -159.18M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -133.3% | -38.69% | -76.46% | -44.42% | -91.49% | -16.85% |
FCF per Share | -0.39 | -0.91 | -1.26 | -2.22 | -2.24 | -3.81 | -2.20 |
FCF Conversion (FCF/Net Income) | 0.90x | 0.80x | 0.90x | 0.89x | 0.95x | 1.57x | 0.93x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GPCR Key Ratios
Structure Therapeutics Inc. (GPCR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -53.06% | -18.6% | -11.86% | -15.14% |
Return on Invested Capital (ROIC) | - | - | -82.15% | -23.09% | -30.32% | -19.88% |
Debt / Equity | - | - | 0.01x | 0.00x | 0.00x | 0.00x |
Interest Coverage | -308.58x | - | -7.67x | - | - | - |
FCF Conversion | 0.80x | 0.90x | 0.89x | 0.95x | 1.57x | 0.93x |
Related:GPCR Dividend History·GPCR Revenue History·GPCR Price History·GPCR P/E History·GPCR Financial Ratios·GPCR Institutional Holders
GPCR SEC Filings & Documents
Structure Therapeutics Inc. (GPCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
GPCR Frequently Asked Questions
Structure Therapeutics Inc. (GPCR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Structure Therapeutics Inc. (GPCR) grew revenue by 0.0% over the past year. Growth has been modest.
Structure Therapeutics Inc. (GPCR) reported a net loss of $170.6M for fiscal year 2025.
Dividend & Returns
Structure Therapeutics Inc. (GPCR) has a return on equity (ROE) of -11.9%. Negative ROE indicates the company is unprofitable.
Structure Therapeutics Inc. (GPCR) had negative free cash flow of $159.2M in fiscal year 2025, likely due to heavy capital investments.